Online inquiry

IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13565MR)

This product GTTS-WQ13565MR is a type of mRNA modified with Pseudo-UTP, which ecodes the monoclonal antibody that targets GPI-APs gene. The antibody can be applied in Benign prostatic hyperplasia research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Aeromonas hydrophila
RefSeq NM_000615.7; NM_001144822.2; NM_000591.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4684; 965; 929
UniProt ID P13591; P19256; P08571
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13565MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12354MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA N63Ab
GTTS-WQ1976MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AGS-15E
GTTS-WQ5328MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CD20-TCB (2:1)
GTTS-WQ9810MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA JS004
GTTS-WQ10227MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LFB-R593
GTTS-WQ7299MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA FPA-008
GTTS-WQ7799MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA GS-HIV
GTTS-WQ2137MR IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ALD-403
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW